Actos (Pioglitazone) Cost in Hawaii 2026: Prices, Insurance, and Savings

Pioglitazone is the generic name for the oral type 2 diabetes medication sold under the brand name Actos. It belongs to the thiazolidinedione (TZD) class and is FDA-approved as a once-daily tablet in 15 mg, 30 mg, and 45 mg strengths, taken as monotherapy or in combination with other diabetes drugs. Pioglitazone has been available as a generic since 2012, and generic thiazolidinediones are, as a class, among the least expensive oral diabetes medications on the U.S. market. That single fact is well established. Nearly everything else on a "cost in Hawaii" page, including specific dollar amounts, specific insurer tiers, and specific Med-QUEST (Hawaii Medicaid) coverage rules, changes often enough that it needs to be verified at the time you fill a prescription rather than taken from a static article.

This page could not confirm current Hawaii-specific cash prices, insurer copay tiers, or Med-QUEST formulary status against a primary source. Where the earlier version of this article stated precise numbers (a $15 cash price, specific HMSA and Kaiser copay ranges, a stated Med-QUEST exclusion, a quoted hepatologist), those claims are either removed, converted to general and clearly labeled statements, or flagged below as requiring direct verification. Treat the checklist near the end of this page as the actionable part of the article.

The one paragraph you can rely on

Pioglitazone is FDA-approved for type 2 diabetes and has been available generically since patent expiration in 2012, which generally makes it one of the cheaper oral diabetes drugs in its class at retail cash prices nationally. It is not a controlled substance, so telehealth prescribing without a prior in-person visit is broadly permitted where state law allows it, including in Hawaii under the state's general telehealth framework. Whether a specific Hawaii insurer, Medicare Part D plan, or Med-QUEST covers it, at what copay, and at what current cash price, are all facts that turn over with formulary years and should be confirmed directly with the plan or pharmacy rather than assumed from any article, including this one.

What is stable versus what changes

Is generic pioglitazone actually inexpensive?

As a class, generic oral diabetes medications that have been off-patent for over a decade, including metformin, sulfonylureas, and pioglitazone, are typically priced well below brand-only classes like SGLT2 inhibitors or GLP-1 receptor agonists at cash-pay rates. This is a general pharmacoeconomic pattern rather than a Hawaii-specific finding. Whether a given Hawaii pharmacy prices a 30-day supply of generic pioglitazone at single digits or in the high teens depends on the pharmacy, the manufacturer it sources from, and whether a discount card is applied, and that number should be checked directly rather than assumed from a national average.

Does Hawaii Medicaid (Med-QUEST) cover pioglitazone?

This could not be confirmed against a current, verifiable Med-QUEST source, so it is stated here as a gap rather than a fact. What is generally true across many state Medicaid programs is that pioglitazone is often placed behind metformin, SGLT2 inhibitors, and GLP-1 receptor agonists on preferred drug lists, in part because of its labeled risks of fluid retention, weight gain, heart failure exacerbation, and a bladder cancer signal that the FDA has required in labeling. Whether Med-QUEST specifically requires prior authorization, and under what clinical criteria, needs to be confirmed with the Med-QUEST Division's current preferred drug list rather than taken from this article.

Commercial insurance and Medicare Part D

Generic drugs that have been available for over a decade are commonly, though not universally, placed on a low generic tier by commercial insurers and Medicare Part D plans, which usually corresponds to a low copay relative to brand-name or specialty tiers. This is a general pattern, not a confirmed statement about HMSA, Kaiser Permanente Hawaii, UHA, or any specific Medicare Part D plan operating in Hawaii in 2026. Formularies and cost-sharing structures are republished annually, and Medicare Part D beneficiaries are also affected by the annual deductible and the federal out-of-pocket cap established under the Inflation Reduction Act, both of which change year to year. Confirm tier placement and copay directly with the plan's current formulary document.

Compounded pioglitazone

Compounded preparations of an FDA-approved drug are legal when prepared by a licensed pharmacy under a patient-specific prescription, subject to federal compounding standards set by the FDA. A compounded product is not an FDA-approved product itself; it has not undergone the same manufacturing review as commercial tablets, and insurance generally does not reimburse it. Compounding is typically relevant only for patients who cannot use a commercial tablet, for example due to a documented excipient allergy or a need for a liquid formulation. State-level compounding oversight (licensure, USP standards) sits on top of this federal framework, and Hawaii-specific compounding rules should be confirmed with the Hawaii Board of Pharmacy rather than assumed.

Telehealth prescribing

Pioglitazone is not a controlled substance, which generally makes it eligible for telehealth prescribing without the added restrictions that apply to controlled medications. General FDA and federal guidance support this framework nationally. Whether a specific Hawaii telehealth statute requires an initial in-person visit, and whether Hawaii's telehealth parity requirements apply to a specific insurer, are state-law questions that should be confirmed with a current legal or regulatory source rather than this article, since state telehealth statutes are amended periodically.

Discount programs and cash-pay options

Third-party discount card services and cash-pay pharmacy models exist and commonly list older generic drugs, including pioglitazone, at low prices. Federally qualified health centers participating in the 340B Drug Pricing Program can offer reduced-cost medications to eligible patients (see HRSA's program overview or the general HHS resources). Specific current prices from any discount card, mail-order pharmacy, or 340B site change often and are not restated here as fixed numbers. Check the live price at the point of fill.

Clinical background: why pioglitazone is prescribed at all

Pioglitazone improves insulin sensitivity in muscle, fat, and liver tissue and was FDA-approved for type 2 diabetes in 1999. Beyond glucose lowering, pioglitazone has been studied in cardiovascular outcome trials and in nonalcoholic steatohepatitis (NASH), now often referred to as MASH. A large randomized outcomes trial in patients with type 2 diabetes and existing macrovascular disease (the PROactive trial) and a placebo-controlled trial in biopsy-confirmed NASH (the PIVENS trial) are both frequently cited in the literature on pioglitazone's non-glycemic effects. This article does not restate their specific effect sizes, because the citation identifiers available for this draft could not be verified against the primary papers, and a mismatched citation is worse than a general description. If you want the exact trial results, search PubMed directly for "PROactive pioglitazone" and "PIVENS pioglitazone NASH" and read the primary paper, or ask your prescriber to walk through the evidence.

Guideline bodies including the American Diabetes Association discuss pioglitazone's role and monitoring recommendations in their annually updated Standards of Care (see diabetesjournals.org/care for the current edition). Off-label use in NASH/MASH is discussed in hepatology literature and guidance documents, but this is an off-label use, not an FDA-approved indication, and the current guideline language should be checked against the latest published version rather than an older summary.

Evidence boundary

Established: pioglitazone is FDA-approved for type 2 diabetes, is available generically, is not a controlled substance, and carries labeled risks including fluid retention, weight gain, heart failure exacerbation, and a bladder cancer signal that prescribers weigh against benefit. Generic pricing for older oral diabetes drugs is typically low relative to newer brand-only classes as a general market pattern.

Plausible but not confirmed for this page: specific Hawaii cash prices, specific HMSA, Kaiser Hawaii, UHA, or Medicare Part D copay tiers, and current Med-QUEST coverage and prior authorization criteria.

Not established here: exact effect-size statistics from the PROactive and PIVENS trials, and the exact current text of any Hawaii telehealth or compounding statute, none of which are restated as numbers in this draft because they could not be verified against a primary source.

Comparing pioglitazone to other diabetes medication classes

This table reflects general class-level pricing and coverage patterns reported across U.S. markets, not confirmed Hawaii-specific numbers.

Verification checklist before you rely on a pioglitazone price or coverage answer

Use this before assuming any number from this page, a search result, or a prior conversation still applies.

Stable facts you generally do not need to re-verify each time:

• Pioglitazone is FDA-approved for type 2 diabetes and generic since 2012
• It is available as 15 mg, 30 mg, and 45 mg oral tablets, taken once daily
• It is not a federally controlled substance
• Baseline and periodic liver function monitoring is part of FDA labeling
• Its labeled risks include fluid retention, weight gain, heart failure exacerbation, and a bladder cancer signal

Facts that expire and must be re-checked at the time of use, with a date attached:

• Current cash price at your specific pharmacy (call or check a live pricing tool; note the date)
• Whether your commercial plan's current formulary places pioglitazone on a preferred or non-preferred tier
• Your Medicare Part D plan's current tier, deductible status, and coinsurance for the current plan year
• Med-QUEST's current preferred drug list status and prior authorization criteria for pioglitazone
• Whether a discount card or cash-pay pharmacy's advertised price is still current (these change without notice)
• Whether a 340B-eligible clinic you plan to use still participates and whether you meet its eligibility criteria
• Current Hawaii telehealth and compounding pharmacy regulations, since state rules are periodically amended

Who to ask, not this article, for each expiring fact: your pharmacy directly for cash price, your plan's member services or current formulary document for coverage and copay, the Hawaii Med-QUEST Division for Medicaid formulary status, and the Hawaii Board of Pharmacy for compounding licensure questions.

When to seek care rather than optimize cost

If you experience sudden swelling, rapid weight gain, shortness of breath, blood in your urine, or signs of liver problems (yellowing skin or eyes, dark urine, unusual fatigue) while taking pioglitazone, contact your prescriber promptly or seek urgent care; these can be signs of the drug's known adverse effects and are not a cost question. Do not stop or adjust a diabetes medication on your own to save money without talking to the prescriber, since uncontrolled blood sugar carries its own risks.